Arvind Ravichandran Featured as a 2023 Tax Rising Star by Law360
June 22, 2023
On June 19, 2023, Cravath partner Arvind Ravichandran was featured as part of Law360’s 2023 “Rising Stars” series as one of the top tax attorneys in the nation under the age of 40. The related profile highlights Arvind’s representation of Occidental Petroleum Corp. in its $57 billion acquisition of Anadarko Petroleum Corp. and Novartis in its $29.8 billion spin‑off of the eye care devices business Alcon.
Arvind mentioned emerging themes in transactional tax work, including the increasing complexity of private equity transactions and evolutions in approaches to early‑stage companies, as people “have gotten more creative in the way that they do deals.” Asked to contemplate how tax law will evolve in the next decade, Arvind reflected on technological developments including advances in artificial intelligence, and society’s increasing embrace of diversity, noting that tax law will “reflect those changes, just like the rest of the world,” concluding “I’m absolutely convinced that it’s going to be better for it.”
Related Practices & Industries
People
- Photo
-
-
J.D., 2012, Columbia Law School
-
B.A., 2009, Columbia College
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
May 22, 2019
Occidental’s $57 Billion Acquisition of Anadarko, Contingent $8.8 Billion Sale of Anadarko African Assets to Total and $10 Billion Investment from Berkshire Hathaway
On May 9, 2019, Cravath client Occidental Petroleum Corporation (“Occidental”) entered into a definitive agreement whereby Occidental will acquire Anadarko Petroleum Corporation (“Anadarko”) for $59.00 in cash and 0.2934 shares of Occidental common stock per share of Anadarko common stock, in a transaction valued at $57 billion, including the assumption of Anadarko’s debt. This follows Occidental’s revised proposal to acquire Anadarko on May 5, 2019. (To read the announcement about the revised proposal, please click here.)
Deals & Cases
April 10, 2019
Novartis’s $29.8 Billion Spin-Off of Alcon
On April 9, 2019, Novartis completed the spin-off of the Alcon eye care devices business into a separately-traded standalone company through a dividend-in-kind distribution to holders of Novartis shares and American Depositary Receipts (“ADRs”), with each holder receiving 1 Alcon share for every 5 Novartis shares or ADRs held on April 8, 2019. Cravath represented Novartis in connection with this transaction, which is valued at approximately $29.8 billion based on first day trading of Alcon Inc.
